these are the lines I like "The four territories covered under the agreement give Exel exclusive rights for the SecureTouch Syringe in the United States, United Kingdom, Germany and Japan. Exel have a strong market presence in another forty countries for which they hold an option for the product however new agreements will need to be formulated for these territories should Exel wish to take up any of these options."
Australia has a population of About 20mill. The market for diabetec and intravenous drug users is 33-50million units per annum. USA Pop is about 280mill or 14 times more. So 462-700mill diabetic and intravenous users. Probably more as they have a higher rate of diabetes.
with the UK, Japan and Germany as well. Probably 11 times our population total 25 times.
As I see it the current share price reflects true value for 50m syringe sales in Australia + Bagot press and the equipment manufacturing line income streams.
"
SFP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
